13.01.2017

Sanochemia Pharmazeutika AG announces grant of patent for Vidon Photodynamic Diagnosis of Bladder Cancer in the USA

Vienna, January 13, 2017 - Sanochemia Pharmazeutika AG, Vienna (ISIN AT0000776307 ISIN DE000A1G7JQ9), announces that the United States Patent and Trademark Office has issued 'Notice of Allowance' for Vidon in Photodynamic Diagnosis (PDD) of bladder cancer.

Vidon (PVP-Hypericin) is one of Sanochemia`s promising pipeline products and is being developed as a game changing technology in the management of bladder cancer. The patent covers the method for improved detection of bladder cancer with Sanochemia's developed PVP-Hypericin formulation. The U.S. patent will protect Vidonuntil 2035.

'The Notice of Allowance for the US application of Vidon for PDD is an important milestone for Sanochemia to secure the long-term value of Vidon, said Dr. Christina Abrahamsberg, CSO of Sanochemia Pharmazeutika AG.

-------------------------------------------------------------------------------------------------------

Bladder cancer is the most common malignancy of the urinary tract. Approximately 75% of initially diagnosed bladder cancers are non-muscle invasive tumors, which means that the tumor is restricted to the mucosa. In 30-80% of the patients, recurrences occur, requiring repeated surgeries. About 45% of bladder cancers will progresses to a muscle-invasive bladder carcinoma.

Early detection, timely and appropriate treatment are therefore essential factors for improving the prognosis of urinary bladder carcinoma patients.

Photodynamic diagnosis (PDD) is a method for better visualization and hence earlier detection of urinary bladder tumors. PDD is more sensitive than standard white-light cystoscopy in the detection of malignant lesions. PDD is based on selective accumulation of a photosensitizer in malignant cells.

Vidon is developed by Sanochemia Pharmazeutika AG as a diagnostic option for patients with non-muscle invasive bladder cancer. A PDD using Vidon makes it easier for the urologist to find malignant tumors. Vidon shows significantly improved tumor detection and an excellent safety profile in clinical trials.

-------------------------------------------------------------------------------------------------------

For further information, please contact:

Bettina Zuccato
Corporate Communications & Investor Relations
Tel.: +43 1/319 14 56-336
b.zuccato(at)sanochemia.at

Sanochemia Pharmazeutika AG published this content on 13 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 13 January 2017 07:20:04 UTC.

Original documenthttp://www.sanochemia.at/de/investoren/pressemeldungen/details/article/grant-of-patent-for-vidonR-in-the-usa/articleBack/103/?cHash=fef00df32a399e896aa9d9721ffdd950

Public permalinkhttp://www.publicnow.com/view/97AD03C9CC348AC20F81D3A940934ABD370F7C94